New cancer drug have been found in a research that has the potential to treat diabetes. Researchers at the Stanford University School of Medicine have discovered a molecular pathway which is a series of interaction among proteins which are involved in the development of diabetes.
The study which was done in mice was to identify a previously unexpected link that was between a low oxygen conditions called hypoxia and also the ability of the cells in the liver to respond to insulin. The drug, (marketed as Eylea or Zaltrap), is used to treat metastatic colorectal cancer and a form of macular degeneration. This drug is a member of the family of proteins that are helpful to inhibit the vascular endothelial growth factor. This works by blocking the growth of the blood vessels into tumors and starve them of oxygen.
Calvin Kuo, MD, PhD, professor of medicine said, "We were surprised to find that this drug currently used in patients for cancer treatment had beneficial effects on diabetes in laboratory mice and could, potentially, in humans. Proteins involved in this pathway could also be targeted for the development of new diabetes therapies," Giaccia, who also is a professor and director of radiation oncology.”
It was published in Nature Medicine.
Read more on Health News
Though all possible measures have been taken to ensure accuracy, reliability, timeliness and authenticity of the information; Onlymyhealth assumes no liability for the same. Using any information of this website is at the viewers’ risk. Please be informed that we are not responsible for advice/tips given by any third party in form of comments on article pages . If you have or suspect having any medical condition, kindly contact your professional health care provider.